@article{Banks:VO2019,
author = "K. C. Banks and D. E. Stalla and F. E. Bunyak and T. A. White and L. G. Schultz and E. A. Giuliano",
title = "Comparison of two cleaning and sterilization protocols of diamond burr tips used in debridement for canine superficial chronic corneal epithelial defects",
year = 2019,
journal = "Veterinary Ophthalmology",
publisher = "Wiley Online Library",
volume = 22,
number = 5,
pages = "614--622"
}
The aim of this study was to develop a novel in vivo corneal model of fibrosis in dogs utilizing alkali burn and determine the ability of suberanilohydroxamic acid (SAHA) to inhibit corneal fibrosis using this large animal model. To accomplish this, we used seven research Beagle dogs. An axial corneal alkali burn in dogs was created using 1 N NaOH topically. Six dogs were randomly and equally assigned into 2 groups: A) vehicle (DMSO, 2 ?L/mL); B) anti-fibrotic treatment (50 ?M SAHA). The degree of corneal opacity, ocular health, and anti-fibrotic effects of SAHA were determined utilizing the Fantes grading scale, modified McDonald-Shadduck (mMS) scoring system, optical coherence tomography (OCT), corneal histopathology, immunohistochemistry (IHC), and transmission electron microscopy (TEM). The used alkali burn dose to produce corneal fibrosis was well tolerated as no significant difference in mMS scores between control and treatment groups (p = 0.89) were detected. The corneas of alkali burned dogs showed significantly greater levels of ?-smooth muscle actin, the fibrotic marker, than the controls (p = 0.018). Total corneal thickness of all dogs post-burn was significantly greater than baseline OCT images irrespective of treatment (p = 0.004); TEM showed that alkali burned corneas had significantly greater minimum and maximum interfibrillar distances than the controls (p = 0.026, p = 0.018). The tested topical corneal alkali burn dose generated significant opacity and fibrosis in dog corneas without damaging the limbus as evidenced by histopathology, IHC, TEM, and OCT findings, and represents a viable large animal corneal fibrosis in vivo model. Additional in vivo SAHA dosing studies with larger sample size are warranted.
@article{Bunyak:Eye-Hessian-2016,
author = "K. M. Gronkiewicz and E. A. Giuliano and K. Kuroki and F. Bunyak and A. Sharma and L. B. C. Teixeira and C. W. Hamm and R. R. Mohan",
title = "Development of a novel in vivo corneal fibrosis model in the dog",
year = 2016,
journal = "Experimental Eye Research",
volume = 143,
pages = "75-88",
keywords = "eye, biomedical, image analysis",
doi = "10.1016/j.exer.2015.09.010",
url = "http://www.sciencedirect.com/science/article/pii/S0014483515300312"
}
K. M. Gronkiewicz, E. A. Giuliano, K. Kuroki, F. Bunyak, A. Sharma, L. B. C. Teixeira, C. W. Hamm, and R. R. Mohan. Development of a novel in vivo corneal fibrosis model in the dog. Experimental Eye Research, volume 143, pages 75-88, 2016.